Print Page  Close Window

Press Release
Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association

Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly

WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced an Oral Presentation at the 18th Congress of the European Neuroendocrine Association (ENEA), which is being held October 17-20 in Wrocław, Poland.

“While current medical therapies can offer meaningful biochemical control of acromegaly, our screening data from an ongoing, global, randomized Phase 3 study, assessing oral vs. injectable (somatostatin receptor ligands) SRLs in acromegaly patients suggests that monthly injectable SRLs may pose significant ongoing challenges to some patients,” said Dr. Maria Fleseriu, FACE, Professor of Medicine and Neurological Surgery and Director of the Northwest Pituitary Center at Oregon Health & Science University, Portland, Oregon. “Patient- reported outcomes are fascinating and reveal a different view of what we consider control. Sixty-six percent (66%) of patients, all biochemically controlled, reported ongoing acromegaly symptoms, of which 83% experienced some symptoms all of the time and 50% indicated some symptoms worsen towards the end of the injection interval. Furthermore, symptoms interfered with daily life, leisure and work activities in a majority of patients and more than half of the patients felt “upset” about being dependent on others. The significant burden of monthly injections displayed in this study can potentially interfere with treatment compliance.”

Details of the Oral Presentation are as follows:
Title: Symptom burden and impact of treatment in patients with acromegaly treated with injectable somatostatin receptor ligands
Presenting author: Dr. Maria Fleseriu
Abstract #: 151
Oral Presentation #: OP01-07
Date & time: Thursday, 18 October 2018, 11:00 - 11:15 AM

For more information on this Oral Presentation at the 18th Congress of the European Neuroendocrine Association, please visit: http://www.enea2018.com/program.html

Similar data were previously presented at the 9th International Congress of the Growth Hormone Research and IGF Societies which was held September 14-18, 2018 in Seattle WA.

About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In September 2017, the Company initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following agreement with the FDA on the design of the trial through a special protocol assessment. Chiasma is headquartered in Waltham, MA with a wholly-owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com

ChiasmaLogo (2).jpg

Chiasma, Inc.